Professor Kosman has been essential in studying the effect of ATH434 on mitochondrial levels. In fact, there is only 5 ATH434 papers and Kosman with his team has been an author in 2 of them.
The first paper was this: https://pubmed.ncbi.nlm.nih.gov/34310628/
The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells
The second paper was published this month: https://pubmed.ncbi.nlm.nih.gov/39317669/
"ATH434, a promising iron-targeting compound for treating iron regulation disorders"
Perhaps the most interesting papers are the posters presented in the Neuroscience meetings this and last year:
https://alteritytherapeutics.com/wp-content/uploads/DB-SfN-2023-poster-for-PR_v2.pdf
https://alteritytherapeutics.com/wp-content/uploads/DB-sfn-2024-poster-10Oct24.pdf
IMO, Kosman's studies demonstrate the effect of ATH434 not only in Parkinsonian diseases but to vascular disease and their complications as atherosclerosis, strokes, brain injuries, etc in which accumulating iron is caused by bleeding of blood. In general he is targeting ferroptosis (a type of programmed cell death dependent on iron) which was only invented some 12 years ago.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.6M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $46.86K | 4.283M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 25268416 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 18128695 | 9 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| ATH (ASX) Chart |